A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

NCT00699842 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Administratively terminated per FDA recommendation

Conditions

Myelodysplastic Syndrome
MDS
Low to Intermediate-1 MDS
Non-deletion 5q

Interventions

DRUG: Lenalidomide

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Collaborators

[object Object]